Eris says issues found at Swiss Parenterals units; impact likely minimal
Published on: April 20, 2026, 11:16 p.m. | Source: CNBC TV18
Eris Lifesciences faces HALMED non compliance observations at Swiss Parenterals plants in Ahmedabad, plans GMP remediation with limited business impact expected. Shares of Eris Lifesciences Ltd ended marginally lower on Monday, April 20, by 0.91% at 1,432.40 on the NSE.
